An Artificial Intelligence System for Anti-VEGF Treatment Decisions in Retinal Diseases: A Randomized Controlled Trial
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Trial Details
| Condition | DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration |
| Intervention | QiLin-assisted; physician only, without QiLin assisted |
| Phase | NA |
| Status | Not_yet_recruiting |
| Participants | 200 |
| Est. Completion | 1 July 2026 |
| Last Updated | 22 May 2026 |
Primary Outcome
Accuracy of the current anti-VEGF injection decision
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: Patients with a diagnosis of nAMD, DME, and RVO; Patients who have completed the loading-dose treatment of anti-VEGF agents; Patients who were willing to participate and provided written informed consent. Exclusion Criteria: Refusal to undergo OCT testing; Refusal to complete the 3-month follow-up period; Screening for a history of intraocular surgery within the past 6 months; Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service